statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Kodiak Sciences Down 26.2% Since Last Earnings Report?

It has been about a month since the last earnings report for Kodiak Sciences Inc. (NASDAQ: KOD). Shares have lost about 26.2% in that time frame, underperforming the S&P 500.
read more...

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif., May 29, 2024 PALO...

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire...

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2...

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer...

Kodiak Sciences price target raised by $2 at UBS, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

UBS Group Boosts Kodiak Sciences (NASDAQ:KOD) Price Target to $5.00

Kodiak Sciences (NASDAQ:KOD - Get Free Report) had its price target hoisted by equities researchers at UBS Group from $3.00 to $5.00 in a report issued on Thursday, Benzinga reports. The brokerage...

Commit To Purchase Kodiak Sciences At $1.50, Earn 10% Using Options

Investors considering a purchase of Kodiak Sciences Inc (KOD) stock, but tentative about paying the going market price of 4.22/share, might benefit from considering selling puts among the...

Kodiak Sciences price target raised by $1 at Barclays, here's why

Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX Research Report), Walgreens Boots Alliance (WB...

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Volume	136,079.00
52-Wk High	$7.77
52-Wk Low	$1.37

KOD Kodiak Sciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals